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Hexachlorobenzene (HCB) was used as a
fungicide until the 1970s, when such use
was prohibited. Considerable amounts are
still generated as waste by-products of
industrial processes and emitted into the
environment. Because of its chemical sta-
bility, persistence, and long-range trans-
port, HCB can be found throughout the
environment and is detectable in human
milk, blood, and adipose tissue. 
In the 1950s, an accidental poisoning in
Turkey revealed several toxic effects of HCB
in humans. Approximately 3,000–5,000
people ingested HCB-treated seed grain
and developed a disease called porphyria
turcica (Gocmen et al. 1986), characterized
by hepatic porphyria and cutaneous skin
lesions caused by a disturbed porphyrin
metabolism (Bickers 1987). Other clinical
symptoms include enlarged liver, spleen,
lymph nodes (LNs), and thyroid, neurolog-
ical symptoms, and arthritis. Infants born
to mothers exposed to HCB developed a
different syndrome called pembe yara, char-
acterized by high mortality, diarrhea, fever,
hepatomegaly, and skin lesions in the
absence of porphyria, but with inﬁltrations
of macrophages and lymphocytes and
infiltrates in the lung (Cam 1960).
Immunotoxic effects were reported in the
Turkish poisoning victims, but also in
occupationally exposed workers in Brazil.
Increased levels of IgM and IgG were
observed, as well as impaired function of
neutrophil granulocytes (Queiroz et al.
1998a, 1998b).
In rats HCB induced hepatic porphyria
and neurotoxic effects (Courtney 1979),
and toxic effects on the reproductive sys-
tem (Jarrell et al. 1998), thyroid function
(Kleiman de Pisarev et al. 1990), and
immune system (Michielsen et al. 1999;
Vos 1986). Because HCB is a lipophilic
xenobiotic, exposure leads to accumulation
in adipose tissue, whereas only a small part
of ingested HCB is metabolized. HCB can
be converted in a cytochrome P450 (CYP)-
dependent manner (Van Ommen and Van
Bladeren 1989) and also via the mercap-
turic acid pathway (Renner 1981). 
Brown Norway (BN) rats are very sus-
ceptible to HCB-induced adverse immune
effects. Exposure caused a dose-dependent
immunostimulation characterized by
enlarged spleen and LNs and increased
serum levels of total IgM, IgG, IgE, and
IgM against single-stranded (ss)DNA.
Furthermore, rats developed inflammatory
skin and lung effects characterized by inﬁl-
trates of eosinophilic granulocytes and
macrophages (Michielsen et al. 1997,
1999). Although both T cells and macro-
phages seem to play an important role in
HCB-induced immunotoxicity in BN rats
(Ezendam et al. 2004), exact mechanisms
are unknown. 
In this study we used DNA microarray
analysis to assess changes associated with
HCB exposure at the gene expression level.
Transcript levels were measured using the
Affymetrix RG U34A GeneChip. BN rats
were exposed to 0, 150, or 450 mg HCB
per kg diet, doses used also in earlier studies
(Ezendam et al. 2004; Michielsen et al.
1997), and gene expression levels were
assessed in spleen, mesenteric lymph nodes
(MLN), thymus, blood, liver, and kidney.
This approach revealed several changes in
line with the known toxic effects but also
revealed novel ones, which may suggest
additional (immuno)toxic effects of HCB
exposure and/or provide more insight into
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Hexachlorobenzene (HCB) is a persistent environmental pollutant with toxic effects in man and
rat. Reported adverse effects are hepatic porphyria, neurotoxicity, and adverse effects on the
reproductive and immune system. To obtain more insight into HCB-induced mechanisms of
toxicity, we studied gene expression levels using DNA microarrays. For 4 weeks, Brown Norway
rats were fed a diet supplemented with 0, 150, or 450 mg HCB/kg. Spleen, mesenteric lymph
nodes (MLN), thymus, blood, liver, and kidney were collected and analyzed using the Affymetrix
rat RGU-34A GeneChip microarray. Most signiﬁcant (p < 0.001) changes, compared to the con-
trol group, occurred in spleen, followed by liver, kidney, blood, and MLN, but only a few genes
were affected in thymus. This was to be expected, as the thymus is not a target organ of HCB.
Transcriptome profiles confirmed known effects of HCB such as stimulatory effects on the
immune system and induction of enzymes involved in drug metabolism, porphyria, and the
reproductive system. In line with previous histopathological findings were increased transcript
levels of markers for granulocytes and macrophages. New findings include the upregulation of
genes encoding proinﬂammatory cytokines, antioxidants, acute phase proteins, mast cell markers,
complements, chemokines, and cell adhesion molecules. Generally, gene expression data provide
evidence that HCB induces a systemic inflammatory response, accompanied by oxidative stress
and an acute phase response. In conclusion, this study confirms previously observed
(immuno)toxicological effects of HCB but also reveals several new and mechanistically relevant
gene products. Thus, transcriptome profiles can be used as markers for several of the processes
that occur after HCB exposure. Key words: Brown Norway rat, DNA microarray analysis, drug
metabolism, estrogen metabolism, genomics, hexachlorobenzene, immunotoxicity, inﬂammation,
oxidative stress, porphyria. Environ Health Perspect 112:782–791 (2004). doi:10.1289/txg.6861
available via http://dx.doi.org/ [Online 7 April 2004]rats were purchased from Harlan
(Blackthorn, UK). Rats were acclimatized
for 1 week before the start of the experi-
ment. They were kept two by two under
standard conditions with food and acidiﬁed
drinking water ad libitum. The diet con-
sisted of a semisynthetic diet (SSP/TOX;
Hope Farms, Woerden, the Netherlands)
with or without crystalline HCB (99%
purity; Aldrich Chemie, Bornem, Belgium)
by mixing of homogeneity. The experi-
ments were approved by the animal experi-
ments committee of the Faculty of
Veterinary Medicine of the Utrecht
University. 
Experimental Protocol
Rats were randomly assigned to different
experimental groups (n = 6) receiving
either control diet or the diet supple-
mented with 150 mg (low dose) or 450 mg
(high dose) HCB/kg. Body weight (bw)
and skin lesions were recorded twice per
week. After 28 days rats were killed by
CO2/O2. Blood was collected in tubes con-
taining EDTA to prevent clotting and
transferred into Fastubes (Endotell,
Allschwill, Switzerland) containing guani-
dinium isothiocyanate in 0.9% NaCl solu-
tion. Tubes were snap-frozen in liquid
nitrogen. Spleen, MLN, thymus (freed
from adjacent LN), liver, and kidney were
collected, weighed, and snap-frozen in
liquid nitrogen. 
In additional experiments for pathol-
ogy, blood, and serum analysis, rats were
exposed to the same dosing regimens. Rats
were killed by a lethal dose of pentobarbital
(Euthesate; 0.3 g/kg bw ip; Ceva Sante
Animal B.V., Maassluis, the Netherlands).
One part of the blood was collected in
EDTA tubes for total and differential
leukocyte counts; the other part was used
for serum analysis. Spleen, MLN, thymus,
liver, and kidney were fixed in phosphate-
buffered 4% formaldehyde; after embed-
ding in Paraplast, 5-µm sections were
stained with hematoxylin and eosin. 
DNA microarray experiment.
Total RNA was obtained by acid guani-
dinium isothiocyanate–phenol–chloro-
form extraction (Trizol; Invitrogen Life
Technologies, San Diego, CA, USA)
(Chomczynski and Sacchi 1987) and puri-
fied on an affinity resin (RNeasy; Qiagen,
Hilden, Germany) according to manufac-
turer instructions. DNA microarray exper-
iments were conducted as recommended
by the manufacturer of the GeneChip sys-
tem (Affymetrix, Inc. 2002) and as previ-
ously described (Lockhart et al. 1996).
Rat specific RG U34A gene expression
probe arrays (Affymetrix, Inc., Santa
Clara, CA, USA) were used containing
8,799 probe sets interrogating primarily
annotated genes. Per tissue and per ani-
mal, one chip was used. The resulting
image files (.dat files) were processed
using the Microarray Analysis Suite 5
(MAS5) software (Affymetrix, Inc.). Tab-
delimited files were obtained containing
data regarding signal intensity (Signal)
and categorical expression level measure-
ment (Absolute Call).
Data Analysis
To determine which genes were diffen-
tially expressed between the three treat-
ment groups, a one-way analysis of
variance (ANOVA) was applied to genes
that had a present call in at least one of the
samples. Genes with a p-value < 0.001
were considered statistically significant.
Group average fold changes were calcu-
lated by using the average of the low- or
high-dose groups compared with the con-
trol group. The annotation of the genes
was determined by using NetAffx (http://
www.affymetrix.com; Liu et al. 2003).
Further information on probe sets was
found in the literature or in the KEGG
database (http://www.genome.ad.jp/kegg/
kegg2.html). Additional data analysis by
principal component analysis (PCA) was
performed using GeneMaths (Applied
Maths, Sint-Martens-Latem, Belgium).
Averages of gene expression levels in con-
trol, low-, and high-dose groups were cal-
culated; low values were cut off using a
lower threshold of 10, and the values were
log transformed before PCA. 
GC–MS Analysis of 
Contamination in the
Hexachlorobenzene Sample
To analyze HCB for contaminating poly-
chlorinated dibenzo-p-dioxins (PCDDs)
and polychlorinated dibenzofurans
(PCDFs), a solution of acetone containing
13C12-labeled internal quantitation stan-
dards (Cambridge Isotope Laboratories,
Woburn, MA, USA) of the PCDDs and
PCDFs was added to dichloromethane.
The solution was brought to a Carbosphere
(Alltech B.V., Zaandam, the Netherlands)
column, then purified on Al2O3, evapo-
rated to dryness, and redissolved in toluene.
Gas chromatography–mass spectrometry
(GC–MS) analyses were performed on a
double-focusing mass spectrometer coupled
to a gas chromatograph. GC separations
were carried out on a nonpolar capillary
column (60 m DB-5MS; 0.25 mm ID,
0.10-µm film thickness; J&W Scientific,
Folsom, CA, USA). Ionization of the sam-
ple was performed in the electron impact
mode. Detection was performed by
selected ion recording.
Results and Discussion
Body Weight Gain, Macroscopic
Skin Lesions, and Organ Weights 
During treatment with the low-dose diet,
body weight increased significantly from
day 10 onward, whereas rats exposed to the
high-dose diet had a significantly higher
body weight on days 10 and 20 (data not
shown). One of the rats in the high-dose
group died after 25 days of exposure to
HCB. Time of onset, severity, and size of
the skin lesions were similar as described
previously (Michielsen et al. 1997).
Increased liver and spleen weights in both
dosing groups were also in accordance with
previous work, as were the observed
histopathological changes in these organs
(Michielsen et al. 1997). In the high-dose
group, kidney weight increased signifi-
cantly, as observed before in Wistar rats
treated with HCB for 25 days (Kennedy
and Wigfield 1990) but not in BN rats
treated with HCB for 21 days (Michielsen
et al. 2002). Histopathological changes
were not observed. Thymus weight
decreased significantly in the high-dose
group. It is likely that this thymus atrophy
is caused by stress, as typical stress-induced
alterations (Kuper et al. 2002) were
observed. No significant differences in
MLN weight were found, but histopathol-
ogy of MLN of the high-dose group
showed comparable morphology as
reported previously (Michielsen et al.
1997).
DNA Microarray Analysis
The PCA plot (Figure 1) of the ratios of
the low- and high-dose groups over the
control group shows that gene expression
in spleen, blood, and liver is dose depen-
dently changed, whereas this is less clear for
MLN, thymus, and kidney. Spleen and
blood cluster close together, as do kidney
and thymus, but liver and MLN are more
distant from those tissues. Most signiﬁcant
changes (p <0 .001) in gene expression
occurred in spleen (679 probe sets), fol-
lowed by liver (346), kidney (232), blood
(144), MLN (104), and thymus (28). The
low number of changes in thymus is not
surprising, as the thymus is not a target
organ of HCB. Remarkably in kidney,
many genes were affected, although this
organ has rarely been described to be
affected by HCB. Furthermore, although
organ weights were increased, no histo-
pathological changes were detected in the
present study. Because not all significantly
changed genes can be included in this arti-
cle, we present only genes associated with
immunology (Tables 1–6), acute phase
responses (APRs) and oxidative stress
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metabolism, porphyria, and estrogen
metabolism (Table 8). 
Figure 2 shows a deduced scheme of
immune cells and mediators involved in
the inﬂammatory response. This scheme is
used to simplify the cascade of reactions
that occur during inﬂammation and to pre-
sent the results in a logical order. The com-
plete list of signiﬁcantly changed probe sets
can be found on the ArrayExpress website
(http://www.ebi.ac.uk/arrayexpress).
Inﬂammatory Response 
Macrophages. In HCB-exposed rats,
macrophage infiltrations were observed in
skin, lung (Michielsen et al. 1997), spleen
(Ezendam et al. 2004; Schielen et al.
1993), and liver (Courtney 1979). As
expected, HCB increased gene expression
of macrophage markers in spleen and
MLN and Kupffer cell markers in liver,
supporting the signiﬁcance of macrophages
in HCB-induced immunotoxicity. 
Proinflammatory cytokines. Gene
expression of the receptor for tumor necrosis
factor (TNF)α and TNFβ (TNF receptor
superfamily, member 1) in MLN, spleen,
and kidney was increased. In addition,
IL-6 gene expression was affected in MLN,
just as the IL-6 signal transducer in kid-
ney. IL-6 is a pleiotropic cytokine that
plays an important role in B-cell differenti-
ation, growth of T cells, and differentia-
tion of macrophages (Naka et al. 2002).
HCB also induced gene expression of
IL-1β in spleen (low-dose group) and
IL-1β–converting enzyme in kidney, an
enzyme that converts IL-1β and IL-18 to
their active form. Gene expression of
IL-18, a cytokine produced mainly by
Kupffer cells, was elevated in liver. 
p38 MAPK signaling pathway. The
mitogen-activated protein kinase (MAPK)
family consists of signal transduction mole-
cules important during inflammation.
HCB induced expression of p38 MAPK
and other MAPKs in kidney. Activation of
p38 MAPK leads to phosphorylation of
several transcription factors, such as signal
transducer and activator of transcription-1
(STAT-1). Gene expression of STAT-1
was increased in liver. Both MAPK
and STAT-1 are important in cytokine
production, and negative regulation of
cytokine signaling occurs at the level of
transcription of these molecules. Proteins
involved in suppression of cytokine pro-
duction are the so-called suppressors of
cytokine signaling (SOCSs). HCB expo-
sure increased gene expression of several of
these proteins, probably to counteract the
high cytokine levels. In spleen, SOCS-2
was upregulated in the low-dose group, but
downregulated in the high-dose group, and
SOCS-3 was upregulated in MLN. In the
thymus, cytokine inducible SH2-contain-
ing protein was upregulated, a protein that
plays a critical role in controlling T-cell
activation (Chen et al. 2003).
Oxidative stress and antioxidants.
Previous studies have shown that HCB expo-
sure induced oxidative stress (Billi
de Catabbi et al. 1997) and increased expres-
sion of antioxidants in the liver (Stonard
et al. 1998). The present work confirms
these findings, as several antioxidants were
induced in liver. Transcriptome profiles
show that antioxidants are also increased in
spleen, MLN, blood, and kidney. The
infiltrated macrophages and granulocytes
probably generate these reactive oxygen
species (ROS). Additional experiments
showed that serum hydroperoxides were
signiﬁcantly increased in HCB-exposed BN
rats (data not shown). Excessive presence of
ROS can activate nuclear factor kappa B,
an important factor in regulating the
inflammatory response (Schreck et al.
1992). In addition, ROS can cause cell
damage, providing danger signals that can
attract inflammatory cells. Therefore,
increased oxidative stress induced by HCB
may play a pivotal role in the observed
immunostimulation.
Acute phase response. Acute phase pro-
teins (APPs) are important in inﬂammatory
responses. HCB increased gene expression
of several APPS, such as heat shock pro-
teins (HSPs) in spleen and MLN. HSPs
protect cells against cellular stress. HCB
also increased gene expression of matrix
metalloproteinase-9 (MMP-9) in spleen
and of the natural inhibitors of MMPs, tis-
sue inhibitor of metalloproteinase-1
(TIMP-1) in liver and TIMP-2 in MLN.
MMPs play an important role in the cleav-
age of membrane components, enabling
leukocytes to extravasate the blood. HCB
also affected transcript levels of other APPs,
such as haptoglobin (a hemoglobin scav-
enger), lipopolysaccharide-binding protein,
orosomucoid (important in immuno-
modulation), and metallothionein and
ceruloplasmin (antioxidants). Negative
APPs (transferrin and its receptor) were also
induced; these proteins are normally down-
regulated during an APR. Synthesis of these
Toxicogenomics | Ezendam et al.






Figure 1. PCA plot of the ratios of low dose versus control (blue circles) or high dose versus control
(red circles).APPs, however, is also dependent on iron
metabolism. HCB induced iron accumula-
tion in the liver (Stonard et al. 1998). The
upregulation of transferrin gene expression
in spleen and kidney suggests that this is
also the case in these organs.
Complement system. Complement
components are also important in inflam-
matory responses. HCB increased gene
expression of several components of the
complement pathway in spleen, blood,
kidney, and liver.
Mast cells. HCB enhanced gene expres-
sion of mast cell enzymes, probably a con-
sequence of complement activation. This
ﬁnding may also be explained by a charac-
teristic of the BN rat, a strain that tends to
respond in a more T helper-2–skewed
fashion. Basal levels of serum IgE are high,
and HCB increases IgE levels even more
(Michielsen et al. 1997). Loading of mast
cells with IgE may result in degranulation
and release of inﬂammatory mediators.
Chemokines and chemokine receptors.
In all analyzed organs, HCB increased
gene expression of chemokines, important
mediators in the recruitment of leukocytes
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Table 1. Spleen: representative genes that changed signiﬁcantly (p < 0.001) after HCB treatment—immune system.a
Fold change
Accession number Gene name HCB low dose HCB high dose
Granulocytes and macrophages
AA957003 S100 calcium binding protein A8 2.8 34
U50353 Defensin 3a  2.5 32
AA946503 Lipocalin 2 1.7 24
L18948 S100 calcium binding protein A9  3.2 19
L06040 12-lipoxygenase 1.9 5.7
M32062 Fc receptor, IgG, low afﬁnity III 1.4 2.0
AA894004 ESTs, highly similar to Capg mouse  1.2 1.4
macrophage capping protein
X73579 Fc receptor, IgE, low afﬁnity II –1.1 –2.3
Mast cells
U67913 Mast cell protease 10 12 42
U67888 Mast cell protease 3 3.4 20
U67907 Mast cell protease 4 precursor  1.5 8.7
M21622 High-afﬁnity IgE receptor  3.2 7.0
U67914 Mast cell carboxypeptidase A precursor  1.8 6.8
U67908 Mast cell protease 5 precursor  1.2 6.0
M38759 Histidine decarboxylase 3.7 4.3
Pattern recognition molecules
AF087943 CD14 antigen 1.1 1.7
Complement
AF036548 Response gene to complement –1.3 20
AA818025 CD59 antigen precursor 1.1 1.7
Cell adhesion molecules 
X05834 Fibronectin 1  1.8 3.5
AJ009698 Embigin 1.4 3.3
Chemokines
U90448 CXC chemokine LIX 1.0 1.9
U17035 Chemokine (CXC motif) ligand 10  1.0 –2.3
Cytokines and cytokine-associated genes
M63122 Tumor necrosis factor receptor 1.3 1.3
AF075382 Suppression of cytokine signaling  1.3 –1.3
M98820 Interleukin 1 beta 1.5 –1.2
M55050 Interleukin 2 receptor beta chain 1.2 –1.4
L00981 Lymphotoxin, tumor necrosis factor alpha –1.1 –1.4
M34253 Interferon regulatory factor 1 –1.1 –1.6
U14647 Interleukin 1 beta converting enzyme 1.1 –1.6
U69272 Interleukin 15 –1.1 –1.7
U48596 MAPK kinase kinase 1 1.0 –1.8
U03491 Transforming growth factor, beta 3 –2.9 –3.0 
Genes associated with T and B cells and MHCII expression
U39609 Anti-nerve growth factor 30 antibody light-chain  1.3 3.8
L22654 Antiacetylcholine receptor antibody rearranged  3.2 1.6
immunoglobulin gamma-2a chain
L07398 Immunoglobulin rearranged gamma-chain V region 1.0 2.4
M18526 Immunoglobulin germline kappa-chain  1.2 1.6
X13016 MRC OX-45 surface antigen 1.1 –1.3
U11681 Rapamycin and FKBP12 target-1 protein –1.0 –1.3
D13555 T-cell receptor CD3, subunit zeta –1.1 –1.4
U31599 MHC class II-like beta chain RT1.Mb –1.0  –1.4
L14004 Polymeric immunoglobulin receptor 1.0 –1.4
D10728 Lymphocyte antigen CD5 –1.2 –1.6
M85193 RT6.2 –1.3 –1.6
U24652 Linker of T-cell receptor pathways –1.0  –1.7
X14319 T-cell receptor active beta-chain, V region –1.2 –2.1
EST, expressed sequence tag. 
aTable contains GenBank accession numbers (http://www.ncbi.nih.gov/entrez/query.fcgi?db=nucleotide) of the cDNA fragments present on Affymetrix RG U34A gene chips, gene
name, and average fold change in expression of both low dose and high dose versus control. Fold changes are calculated with data from five to six rats per group. A one-way
ANOVA was used to determine signiﬁcance; only probe sets that changed signiﬁcantly with p < 0.001 are shown. from the circulation. HCB induced gene
expression of several CXC chemokines and
their receptors: lipopolysaccharide-induced
CXC chemokine (LIX), chemokine (CXC
motif) ligand 10, growth-related oncogene
(Gro) and the CXC chemokine receptor 2
(CXCR2). LIX is a potent neutrophil
chemoattractant, whereas chemokine
(CXC motif) ligand 10 plays an important
role in chemotaxis of activated T cells and
monocytes. Gro is a ligand that binds to
CXCR2, a receptor present on neutro-
phils. HCB induced gene expression of
two CC chemokine receptors: CC
chemokine–binding receptor JAB61, a
receptor that binds monocyte chemoat-
tractant protein-1 and -3, and the receptor
for macrophage inflammatory protein-1α
that is present on neutrophils and
eosinophils (Mantovani et al. 1998). 
Cell adhesion molecules. Chemokines
induce expression of cell adhesion mole-
cules on both endothelial cells and leuko-
cytes. HCB affected gene expression of cell
adhesion molecules in all organs except the
thymus. Intercellular adhesion molecule-1,
vascular cell adhesion molecule-1, and
selectin are endothelial cell adhesion mole-
cules that recognize receptors on hemopoi-
etic cells. Other cell adhesion molecules in
which gene expression was induced by
HCB were fibronectin-1, embigin, CD36,
and glycosylation-dependent cell adhesion
molecule 1 (GlyCAM-1). The latter is
expressed only on high endothelial venules
(HEVs) in LNs. Previous reports have
shown that HCB increased the develop-
ment of HEVs in LNs (Michielsen et al.
1997), which probably results in increased
GlyCAM-1 mRNA expression. 
Granulocytes.  Upregulation of
chemokines and cell adhesion molecules
leads to inﬂux of leukocytes. Data obtained
in this study conﬁrm increased numbers of
monocytes and neutrophilic granulocytes in
blood (unpublished data) and cellular inﬁl-
trations in spleen of BN rats (Michielsen
et al. 1999). In all analyzed organs and blood,
gene expressions for S100 calcium-binding
protein A8 (MRP-8) and A9 (MRP-14) were
upregulated. These proteins are abundantly
present in the cytoplasm of neutrophils,
monocytes, and macrophages (Roth et al.
2003). Other markers associated with granu-
locytes and macrophages that were affected
by HCB were defensin (neutrophils and
macrophages), lipocalin (granulocytes), and
CD24 (granulocytes, monocytes, and
lymphocytes). HCB also induced gene
expression of 12-lipoxygenase- and
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Table 2. MLN: representative genes that changed signiﬁcantly (p < 0.001) after HCB treatment—immune system.a
Fold change
Accession number Gene name HCB low dose HCB high dose
Granulocytes and macrophages
L18948 S100 calcium binding protein A9 2.2 22
AA957003 S100 calcium binding protein A8 2.6 19
M32062 Fc gamma receptor 2.0 2.8
AJ223184 DORA protein (immunoglobulin superfamily, member 6) 1.1 2.6
Pattern recognition molecules
U44129  Mannose-binding lectin 1 1.5 2.6
AF087943 CD14 antigen 1.8 2.5
Cell adhesion 
L08100 Glycam 1 3.1 2.5
Chemokines
U92803 CC-chemokine-binding receptor JAB61 1.9 2.6
AF053312 CC chemokine ST38 precursor 2.4 16
Cytokines 
M26744 Interleukin 6 2.3 4.3
AF075383 Suppressor of cytokine signaling 1.9 2.5
M63122 Tumor necrosis factor receptor  1.2 1.8
AA891209 ESTs, highly similar to interleukin 25 1.2 1.5
Genes associated with T and B cells and MHCII expression
M28671 Rearranged IgG-2b 1.5 3.2
X07189 Immunoglobulin heavy chain constant region 2.5 3.1
M18526 Immunoglobulin germline kappa-chain  1.4 1.8
aTable contains GenBank accession numbers (http://www.ncbi.nih.gov/entrez/query.fcgi?db=nucleotide) of cDNA fragments present on Affymetrix RG U34A gene chips, gene name,
and average fold change in expression of both low dose and high dose versus control. Fold changes are calculated with data from ﬁve to six rats per group. One-way ANOVA was used
to determine signiﬁcance; only probe sets that changed signiﬁcantly with p < 0.001 are shown.
Table 3. Thymus: representative genes that changed signiﬁcantly (p < 0.001) after HCB treatment—immune system.a
Fold change
Accession number Gene name HCB low dose HCB high dose
Granulocytes and macrophages
L18948 S100 calcium binding protein A9 (MRP-14) 1.1 2.0
X14323 IgG receptor FcRn 1.2 1.2
Mast cell
U67911 Mast cell protease 8 precursor 1.5 2.0
Cytokine
AF065161 Cytokine inducible SH2-containing protein  1.2 1.7
Genes associated with B cells
L22654 Antiacetylcholine receptor antibody 
rearranged immunoglobulin gamma-2a chain, VDJC region 1.6 3.7
M18526 Ig germline kappa-chain  2.0 3.2
aTable contains GenBank accession numbers (http://www.ncbi.nih.gov/entrez/query.fcgi?db=nucleotide) of cDNA fragments present on Affymetrix RG U34A gene chips, gene name,
and average fold change in expression of both low dose and high dose versus control. Fold changes are calculated with data from ﬁve to six rats per group. One-way ANOVA was used
to determine signiﬁcance; only probe sets that changed signiﬁcantly with p < 0.001 are shown.Toxicogenomics | Toxicogenomics of hexachlorobenzene
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Table 4. Blood: representative genes that changed signiﬁcantly (p < 0.001) after HCB treatment were functionally grouped—immune system.a
Fold change
Accession number Gene name HCB low dose HCB high dose
Granulocytes and macrophages 
AA957003 S100 calcium binding protein A8 4.7 34
L18948 S100 calcium binding protein A9 4.7 19
L06040 12-lipoxygenase 1.6 3.6
U49062 Heat stable antigen CD24  –1.2 –3.0
Mast cells 
U67913 Mast cell protease 10 17 16
U67911 Mast cell protease 8 precursor  3.9 4.6
X61654 CD63 1.7 2.0
Pattern recognition molecule
AA875213 Peptidoglycan recognition molecule 4.3 7.7
Complement 
AA818025 CD59 protein precursor 1.6 2.6
Cell adhesion 
AF072411 Acid translocase/CD36 antigen 2.4 3.6
AJ009698 Embigin 1.9 2.0
D00913 Intercellular adhesion molecule 1 2.2 1.8
Chemokines
E13732 CC chemokine receptor 1.3 2.4
U90610 CXC chemokine receptor (CXCR4) 2.2 1.1
Anti-inﬂammatory response
AI171962 Annexin 1 (p35)  2.1 4.1
Genes associated with T and B cells and MHCII expression
X76697 CD52/B7 antigen 1.6 2.1
X53517 CD37 antigen –1.2 –1.8
Z49761 RT1.Ma –1.4 –1.8
D13555 T-cell receptor CD3, subunit zeta –1.6 –2.0
X53430 CD3d antigen (T3 delta)  –1.5 –2.0
X53054 RT1.D beta chain –1.4 –2.1
X13044 MHC-associated invariant chain γ –1.5 –2.3
M15562 MHC class II RT1.u-D-alpha chain  –1.3 –2.5
U39609 Anti-nerve growth factor 30 antibody light-chain, –1.5 –2.7
variable and constant regions
aTable contains GenBank accession numbers (http://www.ncbi.nih.gov/entrez/query.fcgi?db=nucleotide) of cDNA fragments present on Affymetrix RG U34A gene chips, gene name,
and average fold change in expression of both low dose and high dose versus control. Fold changes are calculated with data from ﬁve to six rats per group. One-way ANOVA was used
to determine signiﬁcance; only probe sets that changed signiﬁcantly with p < 0.001 are shown.
Table 5. Liver: representative genes that changed signiﬁcantly (p < 0.001) after HCB treatment—immune system.a
Fold change
Accession number Gene name HCB low dose HCB high dose
Granulocytes and macrophages
AA946503 Lipocalin 2 4.3 210
L18948 S100 calcium binding protein A9 (MRP-14) 3.4 28
AA957003 S100 calcium binding protein A8 (MRP-8) 1.1 8.5
X76489 CD9 for cell surface glycoprotein 1.4 3.6
AI104781 Arachidonate 5-lipoxygenase activating protein –1.1 2.3
AA893191 ESTs: phosphatidic acid phosphatase type 2c 1.2 2.0
M55532 Carbohydrate binding receptor (Kupffer cell receptor) 1.1  1.6
S79263 Interleukin-3 receptor beta subunit (colony  1.7 1.3
stimulating factor 2 receptor beta 1, low afﬁnity 
(granulocyte-macrophage)
Mast cell
U67911 Mast cell protease 8 precursor 2.2 2.8
Complement
Z50051 Complement component 4 binding protein, alpha 1.3 2.3
Cell adhesion
D00913 Intercellular adhesion molecule 1 1.2 2.3
Chemokine
D11445 Gro 1.6 11.5
Cytokines
AA892553 STAT-1 1.1 3.3
U77777 Interleukin 18 1.3 1.9
L25785 Transforming growth factor beta stimulated clone 22 –1.5 –1.5
Genes associated with T and B cells and MHCII expression
L22654 Antiacetylcholine receptor antibody,  –1.0 8.8
rearranged immunoglobulin gamma-2a chain, VDJC region
U39609 Anti-NGF30 antibody light-chain 
mRNA, variable and constant regions 1.9 8.7
X68782  Immunoglobulin heavy chain VDJ-region CH1-CH2 1.4 4.6
X53054 RT1.D beta chain 1.5 2.0
aTable contains GenBank accession numbers (http://www.ncbi.nih.gov/entrez/query.fcgi?db=nucleotide) of cDNA fragments present on Affymetrix RG U34A gene chips, gene names,
and average fold change in expression of both low dose and high dose versus control. Fold changes are calculated with data from ﬁve to six rats per group. One-way ANOVA was used
to determine signiﬁcance; only probe sets that changed signiﬁcantly with p < 0.001 are shown.arachidonate 5-lipoxygenase-activating pro-
tein, both involved in leukotriene activation,
which takes place in myeloid cells (Bigby
2002). Gene expression of Fc receptors was
also elevated by HCB, probably because of
the increase in the number of cells bearing
this receptor. The same is true for the
upregulation of gene expression of several
pattern recognition molecules, such as
CD14, mannose-binding lectin, and pepti-
doglycan recognition molecules, present on
monocytes, macrophages, and neutrophils.
This work indicates that HCB exposure
results in a systemic inflammatory
response. To counterbalance this response,
the immune system produces anti-inflam-
matory mediators. HCB exposure induced
gene expression of one of these mediators,
annexin-1, which blocks leukocyte migra-
tion and induces apoptosis in inﬂammatory
cells (Perretti and Gavins 2003). 
T and B Cells and Major
Histocompatibility Complex II
Expression 
Gene expression of T-cell markers such as
CD3 a subunit of the T-cell receptor, was
decreased in spleen, whereas in blood,
HCB decreased gene expression for CD3
and CD37, the latter being a B-cell
marker. Furthermore, HCB increased gene
expression of CD52 or B7 antigen, a
marker present on antigen-presenting cells,
such as B cells and monocytes. This is in
line with previous studies that have shown
a stronger increase of monocytes and gran-
ulocytes in blood after HCB exposure,
resulting in relatively fewer lymphocytes
(Schulte et al. 2002; Vos et al. 1979). In
kidney we observed an increased expression
of OX 45 (homolog to CD2), a membrane
protein involved in the binding to LFA-3,
important in adhesion of T cells to other
cell types and in T-cell activation. HCB
enhanced gene expression of immuno-
globulins in spleen, MLN, liver, and kidney.
This is in line with the observed increase of
serum levels of IgM, IgG, and IgE in BN
rats (Michielsen et al. 1997). Major histo-
compatibility complex (MHC)II gene
expression was decreased in spleen and
blood and increased in liver and kidney.
Autoantibodies 
The anti-acetylcholine receptor antibody
gene (rearranged Ig γ-2a chain) was
upregulated in spleen, thymus, liver, and
kidney. These autoantibodies are associated
with the autoimmune disease myasthenia
gravis (MG), a neurological disease charac-
terized by degeneration of the acetylcholine
receptor and resulting in muscle weakness
(De Baets and Stassen 2002). HCB-
induced neurological effects, however, are
not the same as symptoms described for
MG. Additional experiments performed to
detect antiacetylcholine receptors antibod-
ies (total Ig) in serum did not conﬁrm gene
expression data. HCB exposure also
increased gene expression of anti–nerve
growth factor-30 antibodies in spleen and
liver and downregulated expression in
blood. These antibodies belong to the nat-
urally occurring autoantibodies and are ele-
vated in inflammatory diseases (Dicou
et al. 1996). The exact role of these auto-
antibodies is not yet known. Previously it
was shown that HCB increased IgM anti-
bodies against autoantigens such as ssDNA
(Michielsen et al. 1997; Schielen et al.
1993). Expression of La (= autoantigen
SS-B/La) was induced in kidney. This pro-
tein plays a role in RNA polymerization
and is often a target of autoantibodies
Toxicogenomics | Ezendam et al.
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Table 6. Kidney: representative genes that changed signiﬁcantly (p < 0.001) after HCB treatment—immune system.a
Fold change
Accession number Gene name HCB low dose HCB high dose
Granulocytes and macrophages
L18948 S100 calcium binding protein A9 1.2 9.6
AA957003 S100 calcium binding protein A8 –1.7 3.8
M32062 Fc gamma receptor 1.2 2.7
U10894 Allograft inﬂammatory factor –1.1 2.5
AA946503 Lipocalin 2 1.1 2.0
U49062 Heat stable antigen CD24  1.1 1.8
Complement
X71127 Complement protein C1q beta chain 1.3 4.0
D88250 Complement component 1, subcomponent 1.1 2.9
Cell adhesion
M84488 Vascular cell adhesion molecule 1 1.0 3.0
D00913 Intercellular adhesion molecule 1 1.0 2.0
U82612 Fibronectin 1 1.0 1.6
AI176461 Selectin, endothelial cell, ligand 1.3 –1.5
Chemokine
U17035 Chemokine (CXC motif) ligand 10  –1.1 1.8
Cytokines and cytokine-associated genes 
M63122 Tumor necrosis factor receptor 1.1 1.9
U48596 MAPK kinase kinase 1 1.2 1.9
M92340 Interleukin 6 signal transducer 1.0 1.5
S79676 Interleukin 1 beta converting enzyme –1.2 1.4
U73142 p38 MAPK –1.1 1.3
Genes associated with T and B cells and MHCII expression
L22654 Anti-acetylcholine receptor antibody rearranged  2.6 5.3
immunoglobulin gamma-2a chain, VDJC region
AJ223184 DORA protein (immunoglobulin superfamily member 6) –1.4 2.6
U75411 Antiidiotype Ig M light chain –1.0 2.0
X13016 MRC OX-45 surface antigen 1.1 1.6
AF029240 MHC class Ib RT1.S3 1.0 1.4
S59893 La=autoantigen SS-B/La  1.0 1.4
X56596 MHC class II antigen RT1.B-1 beta chain 1.3 1.3
X53054 RT1.D beta chain 1.5 1.2
M15562 MHC class II RT1.u-D-alpha chain  –1.3 –2.5
aTable contains GenBank accession numbers (http://www.ncbi.nih.gov/entrez/query.fcgi?db=nucleotide) of cDNA fragments present on Affymetrix RG U34A gene chips, gene name,
and average fold change in expression of both low dose and high dose versus control. Fold changes are calculated with data from ﬁve to six rats per group. One-way ANOVA was used
to determine signiﬁcance; only probe sets that changed signiﬁcantly with p < 0.001 are shown.found in several autoimmune diseases
(Huhn et al. 1997). 
Drug-Metabolizing Enzymes 
Cytochrome P450. CYP enzymes are
involved in the oxidative dehalogenation of
HCB (Van Ommen and Van Bladeren
1989). HCB exposure increased gene
expression of several CYPs and of epoxide
hydrolase, an enzyme involved in detoxiﬁ-
cation of epoxides in liver (Table 8). In
spleen, MLN and kidney expression of
CYP enzymes was also induced but to a
lesser extent than in liver. 
Role of dioxin-like contamination of
HCB. Surprisingly, gene expression of
CYP1A1 was strongly upregulated in liver.
This was an unexpected finding, as previ-
ous work showed that HCB induced much
more CYP2B than CYP1A1 (Franklin
et al. 1997). CYP1A1 upregulation is asso-
ciated with 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) or related compounds
that activate the aryl hydrocarbon (Ah)
receptor. It is still the subject of debate if
HCB is a dioxin-like compound. Van
Birgelen (1998) suggested that HCB
should be considered as one, as HCB
meets the criteria for dioxin-like com-
pounds: the ability to bind to the Ah
receptor, induction of dioxin-like effects,
and bioaccumulation. Vos (2000) com-
mented, however, that although TCDD
and HCB share some target organs, the
toxic effects in these systems are quite dif-
ferent. Furthermore the afﬁnity for the Ah
receptor is 10,000 times less for HCB than
for TCDD (Hahn et al. 1989). HCB was
analyzed to investigate whether contami-
nation with dioxin-like compounds was
responsible for the observed effects.
Indeed, HCB was contaminated with
PCDDs and PCDFs, and the toxic equiva-
lent was 187 pg/mg HCB. The calculated
no observed adverse effect level (NOAEL)
of CYP1A1 induction was 0.7–4 ng
TCDD/kg bw/day (Van Birgelen et al.
1995). In our study rats were exposed to
approximately 2 ng/kg bw/day (low dose)
and 6 ng/kg bw/day (high dose). Therefore,
exposure to dioxins and furans is of the
same order of magnitude as the calculated
NOAEL and therefore not likely to be
responsible for the observed strong
increase in gene expression for CYP1A1.
This is not in accordance with previous
work showing that HCB could only mod-
erately or not at all induce CYP1A1 by
HCB (Franklin et al. 1997; Machala et al.
1996). This discrepancy may be explained
by strain differences or by the difference
in detection of CYP1A1 (7-ethoxy-
resorufin-O-deethylase induction versus
gene expression).
Mercapturic acid pathway. The BN rat
degrades HCB also via the mercapturic
acid pathway that involves glutathione con-
jugation catalyzed by glutathione S-trans-
ferase (GST; Renner 1981). As expected,
gene expression of several GSTs was upreg-
ulated in liver. Other phase II enzymes that





One of the main toxic effects of HCB is the
induction of porphyria in humans (Gocmen
et al. 1986) and experimental animals
(Courtney 1979), caused by a disturbance in
heme biosynthesis. In the present study, gene
expression of enzymes involved in heme syn-
thesis were induced. These include aminole-
vulinate (ALA) dehydratase, porphobilinogen
deaminase (hydroxymethylbilane synthase),
and uroporphyrinogen decarboxylase in
spleen and ALA synthase in liver. 
Estrogen/Androgen Metabolism 
Several reports have shown that HCB
exposure induces effects on the reproduc-
tive system. In humans, serum HCB levels
from women exposed during the accident
in Turkey correlated with spontaneous
abortion (Jarrell et al. 1998), and the pro-
portion of male births was reduced in the
group of women that had HCB-induced
porphyria (Jarrell et al. 2002). In monkeys,
HCB decreased estrogen levels (Foster et al.
1995), and in Wistar rats, HCB exposure
reduced serum levels of estrogen and
decreased levels of uterine estrogen recep-
tors (Alvarez et al. 2000). Gene expression
of estrogen sulfotransferase was upregulated
in liver. This enzyme is important in the
sulfation of estrogen, a pathway that inacti-
vates estrogen. The enzyme 17β-hydroxy-
steroid dehydrogenase was downregulated
in the liver. This enzyme catalyzes the
interconversion of testosterone and
androstenedione as well as estradiol and
estrone. Both can lead to lower estrogen
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Table 7. Representative genes that changed signiﬁcantly (p < 0.001) after HCB treatment were function-
ally grouped: APR and oxidative stress.a
Fold change
Accession number Gene name HCB low dose HCB high dose
Spleen
U24441 Matrix metalloproteinase-9 (gelatinase B)  1.1 7.4
M58040 Transferrin receptor –1.1 7.1
AI233261 Glutamate-cysteine ligase 1.2 5.0
K01933 Haptoglobin 1.3 4.2
U06099 Thiol-speciﬁc antioxidant (peroxiredoxin 2) 1.2 3.0
D38380 Transferrin 1.0 2.1
M11794 Metallothionein-1 and -2 1.1 2.0
L33869 Ceruloplasmin 1.0 1.9
AA944397 Heat shock protein 86 1.2 1.8
X07365 Glutathione peroxidase 1.4  1.7
Y00497 Manganese-containing superoxide dismutase  –1.0 1.6
AI170613 Heat shock 10 kD protein 1  1.1 1.3
M21060 Copper-zinc containing superoxide dismutase 1.0 1.3
D00680 Plasma glutathione peroxidase precursor –1.2 –3.5
MLN
D00680 Plasma glutathione peroxidase precursor 2.0 4.3
Y00497 Manganese-containing superoxide dismutase  1.8 2.6
AA817854 Ceruloplasmin 1.0 2.2
S72594 Tissue inhibitor of metalloproteinase-2 1.5 2.0
Blood
AA926149 Catalase 1.7 2.8
AI236795 ESTs, similar to mouse HSP 84  –1.1 –1.6
M11942 70 kd heat-shock-like protein  –1.1 –1.9
Liver
L32132 Lipopolysaccharide binding protein 1.7 8.3
AI169327 Tissue inhibitor of metalloproteinase-1 1.0 6.9
V01216 Orosomucoid 1 3.1 6.1
J02722 Heme oxygenase  1.8 5.2
L33869 Ceruloplasmin 1.4 2.0
Y00497 Manganese-containing superoxide dismutase  1.4 1.6
X12367 Glutathione peroxidase I –1.3 –1.8
Kidney
L33869 Ceruloplasmin 1.3 4.2
D38380 Transferrin 1.3 2.7
X68041 Epididymal secretory superoxide dismutase 1.4 –1.6
aTable contains GenBank accession numbers (http://www.ncbi.nih.gov/entrez/query.fcgi?db=nucleotide) of cDNA frag-
ments present on Affymetrix RG U34A gene chips, gene name, and average fold change in expression of both low dose
and high dose versus control. Fold changes are calculated with data from five to six rats per group. One-way ANOVA
was used to determine signiﬁcance; only probe sets that changed signiﬁcantly with p < 0.001 are shown.Toxicogenomics | Ezendam et al.
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levels. Together, these results indicate that
HCB interferes with estrogen metabolism.
Conclusions
Gene expression proﬁles conﬁrmed known
effects of HCB such as stimulatory effects
on the immune system and induction of
enzymes involved in drug metabolism, por-
phyria, and the reproductive system. New
findings include upregulation of genes
encoding proinflammatory cytokines,
antioxidants, APPs, complement, mast cell
markers, chemokines, and cell adhesion
molecules. Thus, most transcriptome pro-
files are consistent with and complemen-
tary to previous pathological findings and
can be used as markers for several processes
that occur after HCB exposure.
Presumably, after oral exposure to
HCB, macrophages are attracted to organs
such as spleen, lung, and skin and become
activated by HCB. This leads to a cascade
of reactions involving innate immune cells,
as depicted in Figure 2. The gene expres-
sion profiles provide evidence for the
importance of macrophages and granulo-
cytes and mediators released by these cells
in the adverse inflammatory response
against HCB. In this way, co-stimulatory
or danger signals are generated that could
polyclonally activate T cells. Thus, DNA
microarray analysis revealed the complexity
of cells and mediators involved in the
immune response elicited by HCB and
confirms previous work showing the
importance of macrophages and granulo-
cytes (Ezendam et al. 2004; Michielsen
et al. 1999). 
Data obtained in an extensive study
such as this can be used to create a database
with gene expression proﬁles of known toxi-
cants, as has been suggested previously
(Thomas et al. 2002). Chemicals can be
screened by establishing their gene expres-
sion proﬁles and comparing them with pro-
ﬁles of known toxic chemicals. In this way
classes of toxic compounds can be recog-
nized, as has previously been shown for
hepatotoxicants (Hamadeh et al. 2002a,
2002b), and genomics may be an additional
tool in hazard identiﬁcation.
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Figure 2. Hypothetical overview of cells and factors involved in the inflammatory response initiated by
HCB. Assuming that HCB activates macrophages, this would lead to a cascade of reactions, activating
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